|

Effect of Protocolized Magnesium Replacement on Mortality and Atrial Fibrillation in Critically Ill Patients

RECRUITINGPhase 4Sponsored by Scarborough General Hospital
Actively Recruiting
PhasePhase 4
SponsorScarborough General Hospital
Started2025-11-25
Est. completion2027-03-01
Eligibility
Age16 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07173855

Summary

In patients with critical illness, such as severe infections, heart attacks, or respiratory failure, most intensive care units (ICUs) measure magnesium levels and give supplemental doses of magnesium when levels are below certain targets. However, the best targets are unknown. The goal of this clinical trial is to study protocols for magnesium supplementation in people with critical illness, comparing a protocol with higher target level to a protocol with a lower target level. The main question this study aims to answer is whether magnesium supplementation protocols targeting a higher or lower level lead to better 30-day survival and less atrial fibrillation. Participants will not have to do any specific tasks, undergo any additional tests, or complete any surveys.

Eligibility

Age: 16 Years+Healthy volunteers accepted
Inclusion Criteria:

* Age 16 years or older
* Admission orders written to a medical-surgical intensive care unit at a participating site
* Magnesium replacement protocol ordered

Exclusion Criteria:

* Prior enrollment in or withdrawal from MAGNOLIA trial
* Sustained ventricular tachycardia
* Pre-eclampsia
* Myasthenia gravis

Conditions2

Critical IllnessHeart Disease

Browse More Trials

Heart Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.